Drugs / tyrosinase-related protein-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00019383 | Jan 1998 → Jun 2003 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tyrosinase-related protein-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019383 ↗ |
| Known as | TRP1 | “Immunization of Patients With Metastatic Melanoma Using Immunodominant Peptides From the Tyrosinase Protein or Tyrosinase Related Protein-1 (TRP1)” NCT00019383 ↗ |
| Modality | Vaccine | “peptide vaccine” NCT00019383 ↗ |
| Route | Subcutaneous | “Each peptide vaccine is separately emulsified in Montanide ISA-51 and administered subcutaneously into the thigh.” NCT00019383 ↗ |